American College of Neuropsychopharmacology Inc. Neuropsychopharmacology
subscribe to npp
SEARCH
Advanced search
My Account E-alerts Subscribe Register Help
Journal home
Current Issue
Advance Online Publication
Archive
Online sample issue FREE!
Author index
Keyword index
For authors
Editorial Board
Instructions for authors
Aims and scope
Indexed in
Author queries
Online Submission
Customer Services
Subscription information
Journal prices
Order sample issue
Purchase articles,
reprints & permissions
Advertising
Contact NPG
nature.com
Original Article
Neuropsychopharmacology (2002) 26 237-245.10.1038/S0893-133X(01)00313-X

Do Age of Onset and Course of Illness Predict Different Treatment Outcome among DSM IV Depressive Disorders with Atypical Features?

Jonathan W Stewart MD, Patrick J McGrath MD and Frederic M Quitkin MD, DMSc
New York State Psychiatric Institute, New York, NY USA

Correspondence: Dr Jonathan W Stewart, Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, 1020 Locust Street, Room 521 JAH, Philadelphia, PA 19107, Tel.: 215-503-0370, Fax: 215-923-3808, jay.schneider@mail.tju.edu

ABSTRACT

DSM IV defines its atypical features depression modifier mainly by current symptoms. Relative to depressed patients with melancholic features, those with atypical features often present with earlier onset of a more chronic disorder and are less likely to benefit from tricyclic antidepressant (TCA). We, therefore, hypothesized that within depressed patients with atypical features those with illness course most similar to that of melancholia would be most TCA-responsive, those whose illness course least resembled that of melancholia would be least TCA responsive. Two patient groups were treated with TCA, monoamine oxidase inhibitor, or placebo with nonresponders crossed to alternative treatment. One group met DSM IV criteria for atypical features and the other nearly met these criteria. Early onset, chronically depressed patients with DSM IV atypical features had poor TCA response relative to others. Patients with "probable" atypical features (mood reactivity plus one associated atypical feature) and nonresponders crossed to alternate treatment confirmed this. Findings suggest that application of DSM IV atypical features might best be limited to those with early onset of chronic dysphoria.

Keywords: Atypical features; Depression; Tricyclic; Monoamine oxidase inhibitor; Age of onset; Course of illness
  top go to top
Article Links
Send to a friend Send to a friend
Download PDF Download PDF
Full Text Full Text
 Next Article Next Article
 Previous Article Previous Article
 Table of Contents Table of Contents
Privacy Policy Copyright © 2002 by the American College of Neuropsychopharmacology